CPIX
$3.01
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.
Recent News
Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales
CPIX's Q4 revenues jump 31%, while loss narrows year over year as sales of Vibativ, Sancuso and new product Talicia boosted its performance.
Cumberland Pharmaceuticals Inc (CPIX) Q4 2025 Earnings Call Highlights: Revenue Surge and ...
CPIX reports significant revenue growth and global expansion, while navigating increased expenses and financial commitments.
Cumberland Pharmaceuticals Q4 Earnings Call Highlights
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported fourth-quarter and full-year 2025 results and provided a business update during its earnings call, highlighting revenue growth across its portfolio, progress in pipeline programs led by ifetroban, and continued expansion into international markets.
Cumberland: Q4 Earnings Snapshot
CPIX) on Tuesday reported a loss of $1.4 million in its fourth quarter. On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 9 cents. Losses, adjusted for one-time gains and costs, came to 1 cent per share.
Niche Focus & Regulation Shape the Future of Healthcare Firms
CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.